CompletedNot Applicable

Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)

Spain42 participantsStarted 2021-09-30

Plain-language summary

The purpose of this study is to determine whether a multimodal program based on therapeutic exercise and vagal activation techniques for newly diagnosed breast cancer women has better results in terms of neurotoxicity prevenion before or during medical treatments.

Who can participate

Age range18 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * To have 18 years or older * To have a breast cancer diagnosis (Stage I-III) * To be on waiting list for medical adjuvant treatment with risk of central and/or peripheral neurotoxicity. * To have signed the informed consent. * To have medical clearance for participation. Exclusion Criteria: * To have a previous history of cancer or any cancer treatment. * Pregnant patients. * To participate in another intervention that could influence on the outcomes. * To have a neurodegenerative disease that affects central or peripheral nervous system and could influence the results.

What they're measuring

Quality of life (QLQ)

Timeframe: Participants will be followed over 12 months

Trial details

NCT IDNCT04583124

SponsorUniversidad de Granada

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Breast Neoplasm trials